Photocure ASA ( (PHCUF) ) has released its Q3 earnings. Here is a breakdown of the information Photocure ASA presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Photocure ASA is a company focused on providing transformative solutions for bladder cancer patients, primarily through its flagship product, Hexvix/Cysview, which aids in the detection and treatment of non-muscle invasive bladder cancer. Operating in the uro-oncology sector, Photocure has a strong presence in North America and Europe, emphasizing precision diagnostics and patient outcomes.
In the third quarter of 2025, Photocure reported a 12% year-over-year increase in Hexvix/Cysview revenues, reaching NOK 134.1 million. This growth was driven by strong sales in North America and Europe, with North American rigid kit sales increasing by 20%. The company’s commercial EBITDA also saw a significant rise to NOK 16.4 million from NOK 6.9 million in the same period last year.
Key financial highlights include a 14% increase in total unit sales in North America and a 4% increase in Europe. Photocure also expanded its blue light cystoscopy (BLC) capabilities with new installations and partnerships, including a collaboration with Intelligent Scopes Corporation to develop AI for BLC. The company continues to focus on expanding its market presence and enhancing its product offerings.
Looking ahead, Photocure anticipates sustained revenue growth driven by increased adoption of its products and strategic partnerships. The company expects product revenue growth in the range of 8% to 10% on a constant currency basis in 2025, with continued improvements in EBITDA, reflecting its ongoing commitment to advancing precision diagnostics in bladder cancer treatment.